{"id":"liraglutide-metformin","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"5–10","effect":"Headache"},{"rate":"5–15","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL4084119","moleculeType":"Protein","molecularWeight":"3751.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion and slows gastric emptying. Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. The combination provides complementary mechanisms to reduce hyperglycemia.","oneSentence":"Liraglutide stimulates insulin secretion via GLP-1 receptor activation while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:30.484Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05965908","phase":"PHASE3","title":"Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-01-30","conditions":"Polycystic Ovary","enrollment":150},{"nctId":"NCT03856632","phase":"PHASE4","title":"Liraglutide Effect in Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2019-03-18","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT05313529","phase":"NA","title":"LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-10-08","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":396},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07027969","phase":"PHASE4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"NOT_YET_RECRUITING","sponsor":"Ali Aminian","startDate":"2026-02-01","conditions":"Atrial Fibrillation, Obesity and Obesity-related Medical Conditions","enrollment":100},{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06742710","phase":"PHASE4","title":"Liraglutide Treatment in Obese Infertile PCOS Women","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-05-22","conditions":"PCOS, Obesity, Infertility","enrollment":890},{"nctId":"NCT06559722","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-08","conditions":"Type 2 Diabetes","enrollment":510},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03151005","phase":"PHASE4","title":"The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2017-07-01","conditions":"Polycystic Ovary Syndrome (PCOS), Overweight, Obesity","enrollment":70},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT05952882","phase":"PHASE3","title":"Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility","status":"UNKNOWN","sponsor":"Mỹ Đức Hospital","startDate":"2023-11-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":188},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT02960659","phase":"PHASE1, PHASE2","title":"Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-05-09","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05779644","phase":"NA","title":"Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-02-23","conditions":"Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT01779362","phase":"PHASE3","title":"RISE Adult Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-04","conditions":"Prediabetes, Type 2 Diabetes","enrollment":267},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT03172494","phase":"PHASE3","title":"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":720},{"nctId":"NCT05545800","phase":"PHASE3","title":"Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":78},{"nctId":"NCT05360147","phase":"PHASE3","title":"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT02973321","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":296},{"nctId":"NCT04829903","phase":"NA","title":"Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin","status":"COMPLETED","sponsor":"Corporacion Parc Tauli","startDate":"2020-01-02","conditions":"Type 2 Diabetes Treated With Insulin, Obesity, Adolescent Obesity","enrollment":116},{"nctId":"NCT05041673","phase":"NA","title":"Anti-diabetic Drugs and Fatty Liver Management","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-02-23","conditions":"Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2","enrollment":120},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT01541215","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT02686177","phase":"PHASE4","title":"Effect of GLP-1 on Angiogenesis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-18","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT04839237","phase":"PHASE2","title":"The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients","status":"WITHDRAWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2017-12-01","conditions":"Obesity","enrollment":""},{"nctId":"NCT02911948","phase":"PHASE3","title":"A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-09-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":210},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT03010683","phase":"NA","title":"Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Athens","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Coronary Artery Disease","enrollment":60},{"nctId":"NCT02964247","phase":"PHASE3","title":"LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":303},{"nctId":"NCT03235050","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-08-02","conditions":"Diabetes Mellitus, Type 2","enrollment":834},{"nctId":"NCT02205528","phase":"PHASE2","title":"A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-18","conditions":"Diabetes, Diabetes Mellitus Type 2","enrollment":108},{"nctId":"NCT04373967","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-04-29","conditions":"Type 2 Diabetes","enrollment":424},{"nctId":"NCT02730377","phase":"PHASE4","title":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-03-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1991},{"nctId":"NCT03175120","phase":"PHASE3","title":"A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":453},{"nctId":"NCT03225209","phase":"PHASE2","title":"Medically Reproducing Bariatric Surgery","status":"COMPLETED","sponsor":"Moahad S Dar","startDate":"2018-01-31","conditions":"Type 2 Diabetes Mellitus","enrollment":5},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT02292290","phase":"PHASE4","title":"Trial for People With Established Type 2 Diabetes During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":99},{"nctId":"NCT01966978","phase":"PHASE4","title":"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-11","conditions":"Diabetes Mellitus, Type 2, Diabetes","enrollment":157},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT00696657","phase":"PHASE2","title":"A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":415},{"nctId":"NCT01232946","phase":"NA","title":"Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake","status":"COMPLETED","sponsor":"Indiana University","startDate":"2012-01","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT01234649","phase":"PHASE3","title":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08-11","conditions":"Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome","enrollment":153},{"nctId":"NCT02014740","phase":"PHASE4","title":"Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Miami","startDate":"2014-03","conditions":"Type 2 Diabetes, Overweight, Obesity","enrollment":100},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT03421119","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2019-06-20","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT01952145","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-20","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":557},{"nctId":"NCT01392573","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-11-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":413},{"nctId":"NCT02638805","phase":"PHASE3","title":"Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide","status":"COMPLETED","sponsor":"Intarcia Therapeutics","startDate":"2015-12","conditions":"Diabetes Mellitus, Type 2","enrollment":136},{"nctId":"NCT01907854","phase":"PHASE4","title":"Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":407},{"nctId":"NCT02492763","phase":"PHASE2","title":"A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-27","conditions":"Type II Diabetes Mellitus","enrollment":176},{"nctId":"NCT02147925","phase":"PHASE4","title":"Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-08","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":75},{"nctId":"NCT02420262","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-07-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01725126","phase":"PHASE2","title":"To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-10","conditions":"Obesity","enrollment":53},{"nctId":"NCT03353948","phase":"PHASE4","title":"The Effect of a Liraglutide on IVF in Obese PCOS","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-09-01","conditions":"Polycystic Ovary Syndrome, Obesity, Infertility, Female","enrollment":30},{"nctId":"NCT01618162","phase":"PHASE3","title":"The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":435},{"nctId":"NCT01664247","phase":"PHASE3","title":"The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-10-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":346},{"nctId":"NCT01917656","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-01-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":343},{"nctId":"NCT01296412","phase":"PHASE3","title":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-11","conditions":"Diabetes Mellitus, Type 2","enrollment":653},{"nctId":"NCT02298192","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-11-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT02008682","phase":"PHASE4","title":"The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":368},{"nctId":"NCT00856986","phase":"PHASE3","title":"The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":987},{"nctId":"NCT00700817","phase":"PHASE3","title":"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":665},{"nctId":"NCT00614120","phase":"PHASE3","title":"Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":929},{"nctId":"NCT00518882","phase":"PHASE3","title":"Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":467},{"nctId":"NCT01617434","phase":"PHASE3","title":"The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":451},{"nctId":"NCT00318461","phase":"PHASE3","title":"To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1091},{"nctId":"NCT01595789","phase":"PHASE4","title":"The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes","status":"COMPLETED","sponsor":"Haugaard, Steen Bendix, M.D., DMSc","startDate":"2012-05","conditions":"Coronary Artery Disease, Diabetes Mellitus, Type 2","enrollment":41},{"nctId":"NCT01388361","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":413},{"nctId":"NCT03068065","phase":"PHASE4","title":"Antidiabetic Effects on Intrahepatic Fat","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2014-05","conditions":"Non-Alcoholic Fatty Liver Disease, Type2 Diabetes","enrollment":87},{"nctId":"NCT01518101","phase":"PHASE4","title":"Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Type 2 Diabetes","enrollment":62},{"nctId":"NCT01973231","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":404},{"nctId":"NCT01937598","phase":"PHASE3","title":"Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D","status":"COMPLETED","sponsor":"Michael A. Nauck","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT03034941","phase":"PHASE4","title":"Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-04","conditions":"Obesity, PCOS","enrollment":35},{"nctId":"NCT00331851","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":584},{"nctId":"NCT01511198","phase":"PHASE2","title":"Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":223},{"nctId":"NCT00333151","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":576},{"nctId":"NCT01511172","phase":"PHASE2","title":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT02100475","phase":"PHASE3","title":"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":31},{"nctId":"NCT01175473","phase":"PHASE2","title":"Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-08","conditions":"Type 2 Diabetes Mellitus","enrollment":148},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT01516476","phase":"PHASE2","title":"Study of RO6807952 in Patients With Diabetes Mellitus Type 2","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Diabetes Mellitus Type 2","enrollment":2},{"nctId":"NCT01596504","phase":"PHASE2","title":"Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus","enrollment":142},{"nctId":"NCT02909933","phase":"PHASE4","title":"Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2015-07","conditions":"Polycystic Ovary Syndrome, Obesity","enrollment":30},{"nctId":"NCT02535299","phase":"PHASE4","title":"Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2016-06","conditions":"GLP-1；Metformin；Telomere-telomerase System；Par-4","enrollment":200},{"nctId":"NCT01425580","phase":"PHASE2","title":"Liraglutide and Heart Failure in Type 2 Diabetes","status":"COMPLETED","sponsor":"Thomas Nystrom","startDate":"2012-01","conditions":"Congestive Heart Failure, Type 2 Diabetes Mellitus","enrollment":62},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT01658501","phase":"PHASE2","title":"Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM","status":"COMPLETED","sponsor":"PhaseBio Pharmaceuticals Inc.","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":593},{"nctId":"NCT01785043","phase":"PHASE4","title":"Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-03","conditions":"DIABETES Mellitus Type 2 Not Well Controlled","enrollment":13},{"nctId":"NCT02503943","phase":"PHASE4","title":"Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital of Third Military Medical University","startDate":"2015-05","conditions":"Type 2 Diabetes, Overweight, Obesity","enrollment":90},{"nctId":"NCT02501850","phase":"PHASE4","title":"The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2014-10","conditions":"Diabetes Mellitus Type 2","enrollment":40},{"nctId":"NCT02483299","phase":"PHASE4","title":"Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-01","conditions":"PCOS, Obesity","enrollment":40},{"nctId":"NCT01624259","phase":"PHASE3","title":"A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":599}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Victoza 6 mg/ml solution and Glucophage tablets","LIME"],"phase":"marketed","status":"active","brandName":"Liraglutide + metformin","genericName":"Liraglutide + metformin","companyName":"University Medical Centre Ljubljana","companyId":"university-medical-centre-ljubljana","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide stimulates insulin secretion via GLP-1 receptor activation while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}